Abstract: [Problem] To provide a therapeutic method specialized for an inflammatory disease such as intractable vasculitis and an infectious disease, which is different from the previous therapeutic methods, in which a target molecule was not determined, by determining the target molecule useful for treating these diseases. [Solution] According to one aspect of the present invention, a prophylactic and/or therapeutic agent for an infectious disease or an inflammatory disease which contains an antibody recognizing apolipoprotein A2 (APOA2) as an active ingredient is provided.

Abstract: [Problem] To provide a therapeutic method specialized for an inflammatory disease such as intractable vasculitis and an infectious disease, which is different from the previous therapeutic methods, in which a target molecule was not determined, by determining the target molecule useful for treating these diseases. [Solution] According to one aspect of the present invention, a prophylactic and/or therapeutic agent for an infectious disease or an inflammatory disease which contains an antibody recognizing apolipoprotein A2 (APOA2) as an active ingredient is provided.

Abstract: [Problem] To provide a therapeutic method specialized for an inflammatory disease such as intractable vasculitis and an infectious disease, which is different from the previous therapeutic methods, in which a target molecule was not determined, by determining the target molecule useful for treating these diseases. [Solution] According to one aspect of the present invention, a prophylactic and/or therapeutic agent for an infectious disease or an inflammatory disease which contains an antibody recognizing apolipoprotein a2 (APOA2) as an active ingredient is provided.

Abstract: Methods for stabilizing ?-galactosidase, stabilizing ?-glucocerebrosidase, treating a glycolipid metabolic disorder caused by mutation of ?-galactosidase gene, treating a glycolipid metabolic disorder caused by mutation of ?-glucocerebrosidase gene, regenerating the activity of ?-galactosidase, regenerating the activity of ?-glucosidase, treating GM1 gangliosidosis, Morquio-B or Krabbe's disease, and treating Gaucher's disease, include administering a carba-sugar amine derivative represented by the following formula (1) or (2):

Abstract: A boiler apparatus for leading fluid from a plurality of upper walls (2) to (4) to a ceiling wall (7) through a ceiling wall inlet header (11), characterized in that a ceiling wall inlet mixing header (8) is installed between the plurality of upper walls (2) to (4) and the ceiling wall inlet header (11).

Abstract: A carba-sugar amine derivative represented by the following formula (1) or (2) is used as the active ingredient of a ?-galactosidase inhibitor or a glycolipid metabolic disorder treating agent. Wherein each of R1 and R2 independently represents H, an alkyl group, an acyl group, an aryl group or an aralkyl group, with the proviso that both are not H at the same time, and each of R3, R4, R5 and R6 independently represents a hydroxyl group or hydroxyl group having a substituent. Also, R7 represents an alkyl group, and each of R8, R9, R10 and R11 independently represents a hydroxyl group or a hydroxyl group having a substituent.

Abstract: A carba-sugar amine derivative represented by the following formula (1) or (2) is used as the active ingredient of a ?-galactosidase inhibitor or a glycolipid metabolic disorder treating agent. Wherein each of R1 and R2 independently represents H, an alkyl group, an acyl group, an aryl group or an aralkyl group, with the proviso that both are not H at the same time, and each of R3, R4, R5 and R6 independently represents a hydroxyl group or hydroxyl group having a substituent. Also, R7 represents an alkyl group, and each of R8, R9, R10 and R11 independently represents a hydroxyl group or a hydroxyl group having a substituent.

Abstract: A boiler apparatus for leading fluid from a plurality of upper walls (2) to (4) to a ceiling wall (7) through a ceiling wall inlet header (11), characterized in that a ceiling wall inlet mixing header (8) is installed between the plurality of upper walls (2) to (4) and the ceiling wall inlet header (11).

Abstract: A furnace wall comprises: a furnace wall bottom part composed of furnace wall tubes having upward-spiraled fluid passages; a nose part which has nose wall tubes disposed in a middle part of a furnace rear wall adjoining the furnace wall bottom part; and a screen part having screen tubes, wherein the terminal parts of the furnace wall tubes are located lower than the nose part. Consequently, the drain generated in the nose wall tubes while the operation of the boiler is suspended can naturally fall inside the furnace wall tubes located lower than the nose part, and in a case where the header is connected with the terminal parts of the furnace wall tubes, the drain generated in the nose wall tubes can naturally fall inside the header.

Abstract: A furnace wall comprises: a furnace wall bottom part composed of furnace wall tubes having upward-spiraled fluid passages; a nose part which has nose wall tubes disposed in a middle part of a furnace rear wall adjoining the furnace wall bottom part; and a screen part having screen tubes, wherein the terminal parts of the furnace wall tubes are located lower than the nose part. Consequently, the drain generated in the nose wall tubes while the operation of the boiler is suspended can naturally fall inside the furnace wall tubes located lower than the nose part, and in a case where the header is connected with the terminal parts of the furnace wall tubes, the drain generated in the nose wall tubes can naturally fall inside the header.

Abstract: A carba-sugar amine derivative represented by the following formula (1) or (2) is used as the active ingredient of a &bgr;-galactosidase inhibitor or a glycolipid metabolic disorder treating agent.

Abstract: Only suspension type superheaters (52) and (53) are disposed in an outlet of a furnace. These superheaters have heat transfer areas which are so dimensioned that an exhaust gas temperature at downstream of the superheaters is 1000.degree. C. to 1100.degree. C. when the boiler is under a maximum load. An exhaust gas passage downstream of the superheaters (52) and (53) is divided into sub passages along a flow of an exhaust gas, and a damper is disposed in an outlet of each of the sub passages for adjusting a flow rate of the exhaust gas flowing through the respective sub passages. A traverse type reheater (41) is disposed in the sub passage. Since a difference between a temperature (1000.degree. C. to 1100.degree. C.) of the exhaust gas flowing around the reheater (41) and a temperature of steam flowing through the reheater (41) is large, heat exchange can be performed with a high efficiency even through a small heat transfer area.